Education
About Us
Working with TipRanks
Follow Us
MiMedx Group (MDXG)
NASDAQ:MDXG
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.05Last Year’s EPS
0.12Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -3.78%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Neutral
MIMEDX demonstrated a strong start to the fiscal year with growth in the surgical segment and improved cash position. However, challenges in the wound care segment and delays in Medicare reimbursement reforms present ongoing hurdles.Company Guidance
During the MIMEDX First Quarter 2025 operating and financial results conference call, CEO Joe Capper highlighted a 4% year-over-year increase in net sales, reaching $88 million, despite challenging comparisons from the previous year. The company reported an adjusted gross profit margin of 84% and an adjusted EBITDA of $17 million, representing 20% of net sales. MIMEDX ended the quarter with $106 million in cash, marking a $2 million increase during the quarter. The surgical business experienced a 16% growth, attributed to the successful performance of products like HELIOGEN and AMNIOEFFECT, while the wound care business faced challenges due to Medicare reimbursement disruptions. Despite these challenges, the company reiterated its guidance for high single-digit revenue growth for the full year, with a positive outlook for long-term growth post-reform in the Medicare reimbursement landscape.Strong Start to Fiscal Year 2025
MIMEDX reported a 4% year-over-year increase in net sales for Q1 2025, despite a challenging comparison to Q1 2024, which had an 18% growth.
Surgical Business Growth
The surgical segment grew by 16% with contributions across the portfolio, including an uptick in HELIOGEN sales as adoption gains traction.
Cash Position and Profitability
The company ended the quarter with $106 million in cash, a $2 million increase, and reported an adjusted EBITDA of $17 million, representing 20% of net sales.
AMNIOEFFECT and HELIOGEN Performance
AMNIOEFFECT grew by 22% in Q1, and HELIOGEN, a new xenograft, showed promising sequential growth.
---
MDXG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDXG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 30, 2025 | $6.88 | $6.32 | -8.14% |
| Feb 26, 2025 | $8.01 | $8.14 | +1.62% |
| Oct 30, 2024 | $5.69 | $6.85 | +20.39% |
| Jul 30, 2024 | $7.59 | $7.45 | -1.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does MiMedx Group (MDXG) report earnings?
MiMedx Group (MDXG) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is MiMedx Group (MDXG) earnings time?
MiMedx Group (MDXG) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXG EPS forecast?
MDXG EPS forecast for the fiscal quarter 2025 (Q2) is 0.05.
---